This inventor holds 3 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Janssen Pharmaceutica Nv, Astex Therapeutics Limited. Active years: 2019-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019-2026
Title: Suso Jesus Platero: Innovator in Cancer Treatment
Introduction
Suso Jesus Platero is a notable inventor based in Washington Crossing, PA (US). He has made significant contributions to the field of cancer treatment through his innovative approaches and patented technologies. With a total of 3 patents, Platero's work focuses on improving patient outcomes in oncology.
Latest Patents
One of his latest patents is titled "FGFR/PD-1 Combination Therapy for the Treatment of Cancer." This patent outlines methods for identifying cancer patients who are likely to respond positively to treatment with an FGFR inhibitor. The methods involve evaluating biological samples for the presence of FGFR mutants using a specialized gene panel. Additionally, the patent discloses kits and primers designed for the identification of FGFR mutant genes in biological samples, enhancing the precision of cancer treatment.
Career Highlights
Throughout his career, Suso Jesus Platero has worked with prominent companies in the pharmaceutical industry, including Janssen Pharmaceutica NV and Astex Therapeutics Limited. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in cancer therapies.
Collaborations
Platero has collaborated with esteemed colleagues such as Jayaprakash Karkera and Raluca Verona. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise in the field of cancer research.
Conclusion
Suso Jesus Platero's contributions to cancer treatment through his patented innovations demonstrate his commitment to improving patient care. His work continues to influence the landscape of oncology, paving the way for more effective therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

